BACKGROUND: The guaiac fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is user dependent and not specific for human hemoglobin (Hb). The automated-developed, quantitative, immunochemical human Hb FOBT (I-FOBT) is specific, allows for quality control and selection of a suitable Hb level, with optimal sensitivity and specificity, for colonoscopy. MATERIAL/ METHODS: We evaluated a desktop instrument, OC-MICRO (Eiken, Japan), which automatically develops and quantifies 50 fecal tests/hr for Hb; for ease of use, test reproducibility and stability and intra-patient daily I-FOBT variation; clinical evaluation included sensitivity and specificity for neoplasia in patients undergoing colonoscopy. RESULTS: Five hundred patients prepared 3 fecal tests which were quantified for Hb, I-FOBT samples were: (1) repeatedly re-examined; (2) stored at 4 degrees C or 20 degrees C or 28 degrees C and re-examined; (3) I-FOBT levels correlated with colonoscopic findings. Five I-FOBTs re-examined 6 times had no significant changes; 30 tests stored > or = 21 days had a decay/day of: 0.3%+/-0.4 at 4 degrees C (NS), 2.2%+/-1.7 at 20 degrees C (NS) and 3.7%+/-1.8 at 28 degrees C (P<0.05). Receiver operator characteristic curve analysis showed that at the 100 ng Hb/mL I-FOBT level 76.5% of CRCs and advanced adenomas were detected with a specificity of 95.3%. CONCLUSIONS: The instrument provided reproducible results and refrigerated I-FOBT samples were stable 21 days. An I-FOBT level can be chosen to provide optimal sensitivity and specificity for significant neoplasia.
BACKGROUND: The guaiac fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is user dependent and not specific for human hemoglobin (Hb). The automated-developed, quantitative, immunochemical human Hb FOBT (I-FOBT) is specific, allows for quality control and selection of a suitable Hb level, with optimal sensitivity and specificity, for colonoscopy. MATERIAL/ METHODS: We evaluated a desktop instrument, OC-MICRO (Eiken, Japan), which automatically develops and quantifies 50 fecal tests/hr for Hb; for ease of use, test reproducibility and stability and intra-patient daily I-FOBT variation; clinical evaluation included sensitivity and specificity for neoplasia in patients undergoing colonoscopy. RESULTS: Five hundred patients prepared 3 fecal tests which were quantified for Hb, I-FOBT samples were: (1) repeatedly re-examined; (2) stored at 4 degrees C or 20 degrees C or 28 degrees C and re-examined; (3) I-FOBT levels correlated with colonoscopic findings. Five I-FOBTs re-examined 6 times had no significant changes; 30 tests stored > or = 21 days had a decay/day of: 0.3%+/-0.4 at 4 degrees C (NS), 2.2%+/-1.7 at 20 degrees C (NS) and 3.7%+/-1.8 at 28 degrees C (P<0.05). Receiver operator characteristic curve analysis showed that at the 100 ng Hb/mL I-FOBT level 76.5% of CRCs and advanced adenomas were detected with a specificity of 95.3%. CONCLUSIONS: The instrument provided reproducible results and refrigerated I-FOBT samples were stable 21 days. An I-FOBT level can be chosen to provide optimal sensitivity and specificity for significant neoplasia.
Authors: Sietze T van Turenhout; Leo G M van Rossum; Frank A Oort; Robert J F Laheij; Anne F van Rijn; Jochim S Terhaar sive Droste; Paul Fockens; René W M van der Hulst; Anneke A Bouman; Jan B M J Jansen; Gerrit A Meijer; Evelien Dekker; Chris J J Mulder Journal: World J Gastroenterol Date: 2012-10-14 Impact factor: 5.742
Authors: Esmée J Grobbee; Pieter Ha Wisse; Eline H Schreuders; Aafke van Roon; Leonie van Dam; Ann G Zauber; Iris Lansdorp-Vogelaar; Wichor Bramer; Sarah Berhane; Jonathan J Deeks; Ewout W Steyerberg; Monique E van Leerdam; Manon Cw Spaander; Ernst J Kuipers Journal: Cochrane Database Syst Rev Date: 2022-06-06
Authors: Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer; Annekatrien C T M Depla; Pieter Scholten; Ruud J L F Loffeld; Veerle M H Coupé; Chris J J Mulder Journal: BMC Gastroenterol Date: 2012-07-24 Impact factor: 3.067
Authors: Frank A Oort; Sietze T van Turenhout; Veerle M H Coupé; René W M van der Hulst; Eric I C Wesdorp; Jochim S Terhaar sive Droste; Ilhame Ben Larbi; Shannon L Kanis; Edwin van Hengel; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder Journal: BMC Cancer Date: 2011-10-10 Impact factor: 4.430
Authors: Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Arjen P Visscher; Jochim S Terhaar sive Droste; Pieter Scholten; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder; Leo G M van Rossum; Veerle M H Coupé Journal: BMC Gastroenterol Date: 2014-12-21 Impact factor: 3.067